

Spiramycin, HRP conjugate

DAG1291

Lot. No. (See product label)

PRODUCT INFORMATION

Product overview	Spiramycin, HRP conjugate
Antigen Description	Spiramycin is a macrolide antibiotic. It is used to treat toxoplasmosis. Used as an experimental drug in the United states, Spiramycin has been used routinely in Europe. The antibacterial action involves inhibition of protein synthesis in the bacterial cell during translocation. Resistance to spiramycin can develop by several mechanisms and its prevalence is to a considerable extent proportional to the frequency of prescription in a given area.
Source	Aminoglycosides
Conjugate	HRP
Form	concentrate
Characteristic	Each conjugate comprises antigen covalently bound to horseradish peroxide and is suitable as a tracer in immunoassay development

PACKAGING

Storage	Can be stored at 2-8°C for up to 3 months and at -20°C for longer term storage.
----------------	---------------------------------------------------------------------------------

BACKGROUND

Introduction	Spiramycin is a macrolide antibiotic. It is used to treat toxoplasmosis and various other infections of soft tissues. Although used in Europe, Canada and Mexico, spiramycin is still considered an experimental drug in the United States, but can sometimes be obtained by special permission from the FDA for toxoplasmosis in the first trimester of pregnancy.
Keywords	Spiramycin; provamycin; foromacidin; LEUCOMYCIN; KITASAMYCIN BASE; SpiramycinBaseEp97; 2-[12-[5-(4,5-Dihydroxy-4,6-dimethyl-oxan-2-yl)oxy-4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl]oxy-8-(5-dimethylamino-6-methyl-oxan-2-yl)oxy-14-hydroxy-13-methoxy-2,9-dimethyl-16-oxo-1-oxacyclohexadeca-4,6-dien-11-yl]acetaldehyde; Pharmagrade; Spiramycin,Formacidine

REFERENCES

1. Stray-Pedersen B. Treatment of toxoplasmosis in the pregnant mother and newborn child. Scand J Infect Dis 1992; 84(suppl): 23-31.
2. 4.Reynolds JEF, editor. Martindale, the extra pharmacopeia. 30th ed. London: The Pharmaceutical Press, 1993: 202-3.